ReviewCancer diagnosis & prognosis
The NGS and PCR-based Detection of EGFR Mutations in Liquid Biopsy: A Systematic Review and Meta-analysis Compared With Tissue Biopsy in Treatment-naïve Patients With Non-small Cell Lung Cancer.
Review in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Co-Occurring EGFR L858R Mutation and HER2 Amplification in NSCLC Identified by Stepwise Molecular Profiling.The American journal of case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Liquid biopsy (LB) has demonstrated value in managing non-small cell lung cancer (NSCLC) and is widely used for monitoring disease progression in multiple cancers. While the role of baseline circulating tumor DNA (ctDNA) is not yet fully understood, emerging evidence suggests that LB should be integrated into NSCLC management, as pre-treatment ctDNA levels show a strong prognostic association with clinical outcomes. This systematic review and meta-analysis evaluated the diagnostic accuracy of molecular methods including PCR-based assays and next-generation sequencing (NGS) in detecting epidermal growth factor receptor ( Materials and Methods: A systematic search of MEDLINE and LILACS identified studies comparing matched LB and tissue biopsy in treatment-naive patients with NSCLC using polymerase chain reaction (PCR) or NGS. Sensitivity, specificity, positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated using a random-effects model. Results: Twelve studies with 1,314 patients met the inclusion criteria. Most participants were male (59.5%), had adenocarcinoma (82.2%), and stage IV disease (77%). Pooled sensitivity and specificity for NGS in LB were 69% [95% confidence interval (CI)=0.62-0.75] and 90% (95%CI=0.84-0.94), respectively. Regarding real time quantitative polymerase chain reaction (RT-qPCR) sensitivity was 56% (95%CI=0.46-0.65) and specificity 89% (95%CI=0.66-0.97). NGS yielded a PLR of 6.9 and NLR of 0.34; RT-qPCR had a PLR of 5.1 and NLR of 0.49. Conclusion: NGS outperforms RT-qPCR in sensitivity and PLR for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.